- The Great Neuro|Pipeline Brain Drain🔍
- Neuroscience🔍
- Neuroscience renaissance leads to new crop of psychiatric drugs🔍
- Pharma giant Pfizer pulls out of research into Alzheimer's🔍
- Clinical pharmacology in neuroscience drug discovery🔍
- Therapeutic Focus🔍
- The risky business of drug development in neurology🔍
- Why Work in Pharma? Two Words🔍
Pharma Ins and Outs Neuroscience
The Great Neuro-Pipeline Brain Drain - Why Big Pharma Hasn't ...
Nonetheless, novel discoveries in genetics, molecular neuroscience and computer-aided lead generation, as well as altogether out-of-the-box ...
Our ambition is to create a transformational impact for people living with severe neurological conditions and their caregivers.
Neuroscience - neurology and chronic pain - AstraZeneca
We harness advances in data science, artificial intelligence and multi-omics to address the particular challenges associated with treating the central nervous ...
In the field of neuroscience, with many tough-to-treat disorders and high unmet need, our scientists are relentless in their pursuit of raising the ...
Neuroscience renaissance leads to new crop of psychiatric drugs
The drug industry has renewed its interest in neuroscience with new ... pharmaceutical firms were running out of ideas to treat mental illness.
Neuroscience - Pharma partnering - Roche
Our relentless pursuit of scientific innovation is taking us into areas of enormous unmet medical need and progress in treating diseases of the brain and ...
Pharma giant Pfizer pulls out of research into Alzheimer's - BBC
The US-based pharmaceutical giant said it would be ending its neuroscience discovery programmes following a review, and 300 jobs would be lost.
Clinical pharmacology in neuroscience drug discovery: quo vadis?
This article looks at the present situation for carrying out clinical pharmacology in neurosciences and suggests what the future might be in a world where ...
Therapeutic Focus - Neuroscience - Takeda Pharmaceuticals
Our focus in neuroscience is driven by the unmet need of patients with neurologic diseases. Our mission is to bring innovative and potentially disease- ...
The risky business of drug development in neurology - The Lancet
Rebecca Craven investigates. When GlaxoSmithKline (GSK) announced in February, 2010, that it was pulling out of drug discovery in some aspects of neuroscience, ...
Why Work in Pharma? Two Words: Collaboration Opportunities
Pharmaceutical research allows scientists to work as a team on projects that develop cures for different neurological problems.
Regeneron Pharmaceuticals: Delivering Life-transforming Medicines
Push the bounds of science Make life-changing medicines · We move science to medicine because our world is meant for more · REGENERON PERSPECTIVES · Solving the ...
Alkermes – A Global Biopharmaceutical Company
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the field of neuroscience.
Cerevel Therapeutics: Home Page
Unraveling the mysteries of the brain to treat neuroscience diseases Cerevel Therapeutics is working relentlessly to find paths through complexity in an ...
We have assembled an exceptional team of company builders, neuroscience drug developers, and data scientists who have an unparalleled commitment to conquer one ...
Drug Development and Neurohealth | Maastricht University
Which brain drugs does our society need most? Do drugs work the same in everyone? What makes someone vulnerable to brain diseases? What makes them receptive ...
Biohaven: Clinical-stage Biopharmaceutical Company
Fueled by our entrepreneurial structure and experienced management team, we are advancing multiple late- and early-stage drug development programs in ...
Our research in neuroscience - Bristol Myers Squibb
Through our deep understanding of these complex conditions, we are developing medicines with the goal of helping individuals living with neurological and ...
We are one of the only biopharmaceutical companies in the world focusing exclusively on brain diseases, and we're set apart by our specialization.
Professor Novak and Axon have since pioneered the clinical development of tau therapy. Our scientific team has over 20 years' experience in research of ...